168 related articles for article (PubMed ID: 31578396)
21. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
[TBL] [Abstract][Full Text] [Related]
22. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
[TBL] [Abstract][Full Text] [Related]
23. RhoC upregulation is correlated with reduced E-cadherin in human breast cancer specimens after chemotherapy and in human breast cancer MCF-7 cells.
Kawata H; Kamiakito T; Omoto Y; Miyazaki C; Hozumi Y; Tanaka A
Horm Cancer; 2014 Dec; 5(6):414-23. PubMed ID: 25123151
[TBL] [Abstract][Full Text] [Related]
24. miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB.
Gao Y; Zhang W; Liu C; Li G
Sci Rep; 2019 Dec; 9(1):18844. PubMed ID: 31827114
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen inhibits ER-negative breast cancer cell invasion and metastasis by accelerating Twist1 degradation.
Ma G; He J; Yu Y; Xu Y; Yu X; Martinez J; Lonard DM; Xu J
Int J Biol Sci; 2015; 11(5):618-28. PubMed ID: 25892968
[TBL] [Abstract][Full Text] [Related]
26. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
[TBL] [Abstract][Full Text] [Related]
27. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
28. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
[TBL] [Abstract][Full Text] [Related]
29. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.
Chung YL; Sheu ML; Yang SC; Lin CH; Yen SH
Int J Cancer; 2002 Jan; 97(3):306-12. PubMed ID: 11774281
[TBL] [Abstract][Full Text] [Related]
30. Napabucasin Attenuates Resistance of Breast Cancer Cells to Tamoxifen by Reducing Stem Cell-Like Properties.
Liu X; Huang J; Xie Y; Zhou Y; Wang R; Lou J
Med Sci Monit; 2019 Nov; 25():8905-8912. PubMed ID: 31760402
[TBL] [Abstract][Full Text] [Related]
31. Fludioxonil induced the cancer growth and metastasis via altering epithelial-mesenchymal transition via an estrogen receptor-dependent pathway in cellular and xenografted breast cancer models.
Go RE; Kim CW; Jeon SY; Byun YS; Jeung EB; Nam KH; Choi KC
Environ Toxicol; 2017 Apr; 32(4):1439-1454. PubMed ID: 27539251
[TBL] [Abstract][Full Text] [Related]
32. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Lim SC; Kim HS; Kim TH; Lee KY; Ahn SG; Yoon JH; Kang KW
Breast Cancer Res Treat; 2011 Nov; 130(1):73-83. PubMed ID: 21170675
[TBL] [Abstract][Full Text] [Related]
33. Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.
Planas-Silva MD; Waltz PK
J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):11-21. PubMed ID: 17197171
[TBL] [Abstract][Full Text] [Related]
34. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
35. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation.
Paredes J; Albergaria A; Oliveira JT; Jerónimo C; Milanezi F; Schmitt FC
Clin Cancer Res; 2005 Aug; 11(16):5869-77. PubMed ID: 16115928
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
[TBL] [Abstract][Full Text] [Related]
37. Estrogen-mediated down-regulation of E-cadherin in breast cancer cells.
Oesterreich S; Deng W; Jiang S; Cui X; Ivanova M; Schiff R; Kang K; Hadsell DL; Behrens J; Lee AV
Cancer Res; 2003 Sep; 63(17):5203-8. PubMed ID: 14500345
[TBL] [Abstract][Full Text] [Related]
38. DLG5 suppresses breast cancer stem cell-like characteristics to restore tamoxifen sensitivity by inhibiting TAZ expression.
Liu J; Li J; Li P; Jiang Y; Chen H; Wang R; Cao F; Liu P
J Cell Mol Med; 2019 Jan; 23(1):512-521. PubMed ID: 30450766
[TBL] [Abstract][Full Text] [Related]
39. Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer.
BenAyed-Guerfali D; Dabbèche-Bouricha E; Ayadi W; Trifa F; Charfi S; Khabir A; Sellami-Boudawara T; Mokdad-Gargouri R
Mol Biol Rep; 2019 Jun; 46(3):3247-3255. PubMed ID: 30941644
[TBL] [Abstract][Full Text] [Related]
40. Horizontal Transfer of Tamoxifen Resistance in MCF-7 Cell Derivates: Proteome Study.
Semina SE; Scherbakov AM; Kovalev SV; Shevchenko VE; Krasil'nikov MA
Cancer Invest; 2017 Sep; 35(8):506-518. PubMed ID: 28910558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
